DGX

Quest Diagnostics
D

DGX

Arincen63/100B
255.59
USD
0.87
(0.34%)
Pre Open
Fair value202.30Plus+26%77Price 255.59264
Q4 FY2026 · Earnings report
EPS estimate 2.68Revenue estimate 3.04B
OverviewFinancialsForecastEarningsDividendsCompany

Quest Diagnostics revenue 1996–2026

Quest Diagnostics's revenue in Q3 FY2026, the three months to 30 September 2026, was 3.10B USD, up 10.0% on the same quarter a year before. Quest Diagnostics's revenue over the last twelve months was 11.84B USD, up 9.1% on the twelve months before. In fiscal year 2025 it was 11.04B USD, up 11.8% on the year before.

Last updated 7 Nov 2026 · Next report 9 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202611.84B+9.13%3.93B1.13B
FY202531 Dec 202511.04B+11.78%3.52B992.00M
FY202431 Dec 20249.87B+6.70%3.24B871.00M
FY202331 Dec 20239.25B-6.38%3.07B854.00M
FY202231 Dec 20229.88B-8.39%3.43B946.00M
FY202131 Dec 202110.79B+14.32%4.21B2.00B
FY202031 Dec 20209.44B+22.15%3.63B1.43B
FY201931 Dec 20197.73B+2.59%2.69B858.00M
FY201831 Dec 20187.53B-2.31%2.61B736.00M
FY201731 Dec 20177.71B+2.58%2.99B772.00M
FY201631 Dec 20167.52B+0.29%2.90B645.00M
FY201531 Dec 20157.49B+0.78%2.84B709.00M
FY201431 Dec 20147.44B+4.04%2.80B556.00M
FY201331 Dec 20137.15B-3.20%2.82B849.00M
FY201231 Dec 20127.38B-1.70%3.02B555.70M
FY201131 Dec 20117.51B+1.92%3.12B470.60M
FY201031 Dec 20107.37B-1.16%3.05B720.90M
FY200931 Dec 20097.46B+2.84%3.13B729.10M
FY200831 Dec 20087.25B+8.12%2.99B581.50M
FY200731 Dec 20076.70B+6.96%2.74B339.94M
FY200631 Dec 20066.27B+13.90%2.57B586.42M
FY200531 Dec 20055.50B+7.36%2.25B546.28M
FY200431 Dec 20045.13B+8.20%2.14B499.20M
FY200331 Dec 20034.74B+15.33%1.97B436.72M
FY200231 Dec 20024.11B+13.24%1.68B322.15M
FY200131 Dec 20013.63B+6.04%1.48B162.30M
FY200031 Dec 20003.42B+55.14%1.45B102.05M
FY199931 Dec 19992.21B+51.19%886.20M-3.40M
FY199831 Dec 19981.46B-4.59%644.70M26.90M
FY199731 Dec 19971.53B-5.42%653.20M-22.30M
FY199631 Dec 19961.62B—605.42M-625.96M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Quest Diagnostics revenue growth by segment

Q3 FY2026 against Q3 FY2025

Diagnostic Information Services Business3.04B
+10.2%

Quest Diagnostics revenue by segment over time

Diagnostic Information Services Business Other Segments Routine clinical testing services Anatomic pathology testing services All other services COVID-19 Testing Services Gene-based and esoteric testing services
Fiscal yearDiagnostic Information Services BusinessOther SegmentsRoutine clinical testing servicesAnatomic pathology testing servicesAll other servicesCOVID-19 Testing ServicesGene-based and esoteric testing services
FY202510.79B +12.2%— — — — — —
FY20249.61B +7.1%— — — — — —
FY20238.98B -6.6%276.00M +0.7%— — — — —
FY20229.61B 274.00M — — — — —
FY2021— — 4.29B +11.9%553.00M +14.7%294.00M -1.3%2.77B +1.7%2.88B +37.2%
FY2020— — 3.84B -8.8%482.00M -16.8%298.00M 2.72B 2.10B
FY2019— 321.00M -1.8%4.21B -0.3%579.00M +0.2%— — —
FY2018— 327.00M -3.5%4.22B -2.1%578.00M -5.6%— — —
FY2017— 339.00M -10.1%4.31B +3.1%612.00M -1.9%— — —
FY2016— 377.00M -28.6%4.18B 624.00M — — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Quest Diagnostics's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.